Discontinue treatment if skin irritation occurs; if favorable response does not occur promptly in dermatological infection. Not for oral, ophth or intravag use. Avoid use on face, groin or axillae; contact w/ eyes. Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression w/ potential for glucocorticosteroid insufficiency after treatment w/drawal. Cushing's syndrome, hyperglycemia & glucosuria. Periodically evaluate for evidence of HPA axis suppression in patients applying topical steroid to large surface area or areas under occlusion. Institute appropriate antifungal or antibacterial agent in presence of dermatological infection. Refer to ophthalmologist for evaluation of possible visual disturbances causes including cataract, glaucoma or rare diseases (eg, central serous chorioretinopathy) in patient presenting w/ symptoms (eg, blurred vision or other visual disturbances). Pregnancy & lactation. Adrenal suppression especially in infants & childn. Ped patients (more susceptible to topical corticosteroid-induced HPA axis suppression & Cushing's syndrome).
Sign Out
